<DOC>
	<DOC>NCT00095537</DOC>
	<brief_summary>The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments. The study will also test for other proteins that may be affected by BMS-599626; and the level of study drug in the blood will be studied.</brief_summary>
	<brief_title>BMS-599626 in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Diagnosis of metastatic cancer that has progressed on currently available therapies; At least 3 month life expectancy; Primary cancer must be solid (nonhematologic); Adequate bone marrow, liver &amp; kidney function; Negative pregnancy test. Serious, uncontrolled medical disorder; Individuals not willing or able to use an acceptable method to avoid pregnancy for the entire study period and for at least 3 months after the study; Pregnant or breastfeeding women; Patients with known brain metastasis; Uncontrolled or significant cardiovascular disease; Anticancer therapy within 26 weeks prior to study drug (depending on the therapy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Solid tumors</keyword>
	<keyword>cancer</keyword>
	<keyword>HER-2-expressing tumors</keyword>
</DOC>